ReShape Lifesciences Inc. (RSLS)
Stock Price:
$4.45 USD
0.00 (0.00%)
Updated December 2, 4:00 PM EST - Market closed
Key Info
| Market Cap |
24.86M |
| Revenue (ttm) |
12.14M |
| Net Income (ttm) |
-38.15M |
| Shares Out |
6.97M |
| EPS (ttm) |
-5.65 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 2 |
| Last Price |
$4.45 |
| Previous Close |
$4.45 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
4.45 |
| Day's Range |
4.45 - 4.75 |
| Day's Volume |
100 |
| 52-Week Range |
0.00 - 4.75 |
More Stats
| Market Cap |
24.86M |
| Enterprise Value |
33.27M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
6.97M |
| Float |
n/a |
| EPS (basic) |
190.60 |
| EPS (diluted) |
-5.65 |
| FCF / Share |
-1.20 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
1.84 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
2.05 |
| PB Ratio |
1.46 |
| Revenue |
12.14M |
| Operating Income |
-12.37M |
| Net Income |
-38.15M |
| Free Cash Flow |
-8.35M |
| Net Cash |
-8.41M |
| Net Cash / Share |
-1.50 |
| Gross Margin |
76.63% |
| Operating Margin |
-101.83% |
| Profit Margin |
-314.20% |
| FCF Margin |
-68.79% |
| ROA |
-16.84% |
| ROE |
-5,369.60% |
| ROIC |
-1,114.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
537,600
Current: $4.45
High
537,600
Target: 537,600
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 15.09 | 0.61 | 0.57 | 0.79 | 0.29 | - | - | 0.31 | - | - |
| Revenue Growth | 2385.83% | 6.65% | -27.65% | 169.4% | - | - | - | - | - | - |
| Gross Profit | 9.31 | 0.44 | 0.24 | 0.36 | 0.17 | - | - | 0.08 | - | - |
| Operating Income | -24.46 | -38.55 | -28.05 | -22.80 | -27.87 | -25.59 | -24.73 | -22.55 | -25.26 | -16.18 |
| Net Income | -74.21 | -81.15 | -33.82 | -23.36 | -25.50 | -26.13 | -25.78 | -23.46 | -26.00 | -17.35 |
| Shares Outstanding | 1.73 | 0.01 | - | - | - | - | - | - | - | - |
| Earnings Per Share | -42.93 | -9,023.14 | -773,439.38 | -9,464,657.36 | -75,396,978.69 | -101,947,448.35 | -124,065,042.29 | -156,176,490.50 | -227,647,087.85 | -545,294,187.18 |
| Operating Cash Flow | -14.20 | -27.49 | -24.59 | -20.66 | -22.61 | -19.38 | -18.43 | -22.48 | -19.94 | -13.66 |
| Capital Expenditures | -0.01 | -0.05 | -0.14 | -0.01 | -0.04 | -0.09 | -0.42 | -0.08 | -0.25 | - |
| Free Cash Flow | -14.21 | -27.54 | -24.73 | -20.67 | -22.64 | -19.47 | -18.84 | -22.56 | -20.19 | -13.67 |
| Cash & Equivalents | 2.99 | 5.55 | 10.16 | 3.31 | 7.93 | 11.62 | 23.30 | 22.51 | 29.69 | 37.37 |
| Total Debt | 5.41 | - | - | - | 1.27 | 2.98 | 6.87 | 9.68 | 5.19 | 5.91 |
| Net Cash / Debt | -2.42 | 5.55 | 10.16 | 3.31 | 6.66 | 8.64 | 16.43 | 12.82 | 24.50 | 31.46 |
| Assets | 39.66 | 46.27 | 88.70 | 7.04 | 11.59 | 14.39 | 26.39 | 26.10 | 32.49 | 38.69 |
| Liabilities | 15.55 | 14.61 | 12.34 | 4.10 | 7.91 | 7.72 | 11.71 | 14.22 | 12.44 | 8.98 |
| Book Value | 24.11 | 31.66 | 76.37 | 2.94 | 3.67 | 6.66 | 14.68 | 11.87 | 20.04 | 29.71 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ReShape Lifesciences Inc. |
| Country |
United States |
| Employees |
38 |
| CEO |
Barton Bandy |
Stock Information
| Ticker Symbol |
RSLS |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
OTCMKTS: RSLS |
| IPO Date |
November 15, 2007 |
Description
ReShape Lifesciences, a medical device company, focuses on the design, development, and commercialization of technology to treat obesity and metabolic diseases. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in morbidly obese patients without permanently cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.